Covid-19 vaccine may be ready in 12-18 months: WHO chief scientist

Developing a vaccine against Covid-19 is the most pressing challenge and by the current estimates, funding to the tune of $18.1 billion will be required to deliver two billion doses by the end of 2021, Dr Soumya Swaminathan, chief scientist of World Health Organisation, said on Friday.

Over 200 vaccine candidates are at different stages of development and 15 are in human clinical trials. ‘There is a hope that we can have a vaccine in 12-18 months’ time,’ Dr Swaminathan said while addressing a virtual media conference on Friday.

Dr Swaminathan presented the investment requirements to develop the vaccines as rapidly as possible, and manufacture at the right volumes without compromising on safety. She said that in addition to upfront investment in research and development and manufacturing, commitments from high-income and upper middle-income countries were needed to procure 950 million doses through the COVAX Facility, and to ensure that vaccines can be delivered at the greatest possible speed.

Responding to queries on leading vaccine candidates, Dr Swaminathan said AstraZeneca had the largest global commitment and was the leading candidate, in terms of timing . ‘They have advanced to Phase 2 trials and are planning Phase 3 in many countries. Moderna also has plans to go to Phase 3 of clinical trials by mid-July, but AstraZeneca has a more global scope where they are planning clinical trials,’ said Dr Swaminathan.

‘But until we see results from clinical trials, the efficacy and safety of these candidates remain unknown. That underlines the need to invest in clinical development of multiple vaccine candidates, thus maximising the chances of success,’ Dr Swaminathan told The Indian Express.

The University of Oxford and AstraZeneca ‘s experimental vaccine was the first to enter the final stages of clinical trials. The vaccine is also undergoing tirals in South Africa and Brazil, with Serum Institute of India investing $100 million to mass produce one billion doses for India, and other low and middle-income countries.

‘There has been tremendous commitment from the private sector as they do see it as their corporate social responsibility, and we are seeing a lot of practical steps being taken, where vaccine developers are tying up with generic companies, which can manufacture at scale, and we sincerely hope this unprecedented collaboration can lead to a vaccine in record time,’ said Dr Swaminathan.

‘The good news is that we have a globally diversified portfolio of vaccine candidates, with significant contributions from large pharmaceutical companies in the West and similar ones from China and India.. Also, a wide number of countries are at early stage of vaccine projects, and there will be one or two that will be at the front of the race but we need to be humble — we may be super lucky if we can make the world’s fastest vaccine with 12-18 months,’ said Sir Andrew Witty, Special Envoy for the Access to COVID-19 Tools Accelerator (ACT-Accelerator), while responding to queries at the virtual media conference.

The ACT-Accelerator, launched at the end of April, brings together governments, health organisations, scientists, businesses, civil society and philanthropists, who have joined forces to expedite an end to the pandemic. On Friday, at the webinar cum virtual press conference organised by the World Health Organisation, the ACT- Accelerator published its consolidated investment case.

According to Dr Bruce Aylward, WHO senior advisor and head of the ACT-Accelerator Coordination Hub, who coordinated the webinar, the plans called for US $31.3 billion in funding for diagnostics, therapeutics and vaccines, of which US $3.4 billion has so far been pledged.

The ACT-Accelerator is led by the work of partner organisations collaborating under four pillars. The ACT-Accelerator’s vaccines pillar has created a Global COVID-19 Vaccine Facility, through which countries can work together to share risks by accessing a wide portfolio of vaccine candidates.

CBSE, ICSE to announce class 10, 12 board exam results by July 15

PTI,

The Supreme Court on Friday permitted the Centre and the CBSE to cancel the remaining board examinations due to COVID-19 pandemic and gave a go-ahead to its scheme to award marks to students for the cancelled papers scheduled to be held in July.

A bench of Justices A M Khanwilkar, Dinesh Maheshwari and Sanjiv Khanna permitted the CBSE to issue a notification for the cancellation of the examinations.

Solicitor General Tushar Mehta, appearing for the Centre and the CBSE, said that the assessment scheme will consider marks achieved by students in last three papers of board exams.

Both CBSE and ICSE told the top court that the results of the class X and XII board exams can be declared by mid of July.

The top court was hearing pleas seeking relief, including scrapping of remaining exams of Class 12 scheduled from July 1-15, in view of increasing number of COVID-19 cases. Similar relief was sought by the ICSE Board also.

PAN Card-Aadhaar Card Linking Deadline extended till March 31; Check details

The last date for PAN-Aadhaar linking has been extended by the government. As per the notification, the PAN Card-Aadhaar Card linking last date has been extended till March 31, 2021. The previous deadline for linking PAN and Aadhaar was June 30, 2020. The extension in PAN-Aadhaar link deadline comes as good news for those PAN cardholders who have not yet reportedly linked their PAN with Aadhaar. They now get a few more months to complete the process, which takes just a few minutes.

If you already have the PAN card and are eligible to obtain Aadhaar number or you have already acquired one, then you are required to intimate the Aadhaar number to the Income Tax department.

Your PAN Aadhaar linking needs to be completed else the PAN will become ‘inoperative’.

Once the PAN becomes inoperative, one will not be able to undergo several transactions where PAN is required to be quoted mandatorily. The income tax department has specified 18 financial transactions where quoting of PAN is mandatory by the individual. In such cases, the transactions could be carried out only when the PAN and Aadhaar are linked thus making the PAN re-active.

To link Aadhaar with PAN card, one may go to the e-filing website of the income tax department. One may use log-in credentials or even without logging, the linking of Aadhaar and PAN can be done. The income tax department has made it clear that for filing of ITR, Aadhaar and PAN linkage is mandatory unless specifically exempted.

For PAN-Aadhaar linking, you must ensure that name, date of birth and gender mentioned by you are same on both PAN and Aadhaar. The Aadhaar number and the name on Aadhaar card should be exactly the same as printed on the Aadhaar card.

PAN and Aadhaar can also be linked through SMS to 567678 or 56161 through your registered mobile number. The format of the SMS is: UIDPAN<SPACE><12 Digit Aadhaar Number><SPACE><10 Digit PAN> For Example: UIDPAN 100023456789 XXYZ0123X.

As per income tax rules, PAN Aadhaar linking is mandatory. For new PAN seekers, the Income Tax Department allows the creation of Aadhaar-based instant PAN on the e-filing website. ‘Aadhaar-based instant PAN allotment service is to allot PAN in near-real time. You are required to quote a valid Aadhaar number issued by Unique Identification Authority of India (UIDAI) and is not linked with any PAN. The e-KYC data of that Aadhaar number is exchanged with the Unique Identification Authority of India(UIDAI). After due process of e KYC data in Income-tax database, you get a PAN,’ the Income Tax Department says on its website.

Karnataka minister K Sudhakar’s wife, daughter test positive for COVID-19

0

Bengaluru: Karnataka Medical Education Minister K Sudhakar’s wife and daughter have tested positive for COVID-19. Fortunately, the samples of the MLA and his two sons have returned negative for coronavirus.

“Test results of our family members have come. Unfortunately, my wife and daughter have tested positive for #Covid19 and are undergoing treatment. My two sons and myself have tested negative. I am grateful to everyone for their best wishes and prayers,” Sudhakar tweeted.

Notably, the Kerala minister’s father P N Keshava Reddy tested positive for COVID-19 on Monday.

He was admitted to hospital after complaining of fever and cough.

Earlier, a domestic help of Sudhakar had tested positive for the deadly contagious disease and was admitted to a hospital.

Sudhakar, an MLA from Chikkaballapura, was quarantined along with three other ministers in April for coming in contact with a journalist who had tested positive for COVID-19.

Parents do ‘tweetstorm’ to oppose Karnataka ban on online classes

0

Parents of students from various private schools took to Twitter on Sunday to bring to the government’s attention that they want online classes to resume for their wards, and want the ban on online classes revoked.

Karnataka Education Department had passed an order last week banning all virtual classes (live and recorded) for classes up to standard 5. The government is currently consulting with an expert committee to draw up guidelines on online classes for school students.

Parents tweeted, saying the government should work on ensuring access, instead of banning classes. Parents also noted that the government had not done any forward planning and paid attention to the issue during April and May, when schools were shut.

“Setting up the committee after denying everyone education is just a means to hide the incompetence of the ministry. Why deny access to everyone? Work on ensuring access” one tweet read.

“Instead of working on ensuring access during April and May, the minister has chosen to ban education altogether in June. Couldn’t he have setup the committee in April. Why wake up only in June and now hiding behind the committee?”

 

Teachers too joined the tweetstorm pledging their support for online classes. Quite a few schools have laid off or cut salaries of teachers since the government has told parents that they need not pay fees for now, till classes resume.

 

Over the last few weeks, many have opposed online classes as it would adversely affect those students who do not have access to a laptop, mobile phone or internet. With most parents working from home, many who have laptops and mobiles are unable to spare it for their wards. To combat this, the government had proposed to have televised classes for students as most children have TV in their homes. Moreover, schools were trying to complete the syllabus through online classes, thereby making students glued to the screens for hours.

Rajesh Bhat, who is part of the All India Save Education campaign, says that educational institutions are trying to put pressure on the government. “Private international schools badly want online classes (to continue). Many schools have bought software paying lakhs of rupees from software developers. Now, the ban on online classes have affected them. Many schools have not gotten admissions after the ban on online classes.”

Education Minister Suresh Kumar had told TNM that the ban is only temporary and the committee was looking at curtailing hours of learning and cutting down the syllabus.

However, if the government does not make its position clear by next week, it could spell more trouble for schools and agitate parents who want online classes to resume.

Favipiravir: All You Need to Know About the New Covid-19 Medicine and its Effects on Patients

New Delhi: Mumbai-based Glenmark Pharmaceuticals has received approvals from Drug Controller General of India to manufacture and market Favipiravir, an anti-viral drug, to treat Covid-19 patients. The drug is likely to be available in the market in the next few days. What is this drug and what improvement has it shown in Covid-19 patients? News18 explains:

What is Favipiravir?

Favipiravir is an anti-viral drug and it is approved in Japan for treating influenza. It is currently being tested in 18 clinical trials for Covid-19 and results from two studies have shown a positive outcome, while data from other trials is awaited.

What is the Glenmark drug approved by the Drug Controller General of India?

Based on Phase-3 data, the company obtained approval for manufacture and marketing of antiviral drug Favipiravir, which has been branded as FabiFlu, an oral medication. The approval is for emergency restricted use only for treatment of mild to moderate Covid-19 patients. The approval’s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

According to a press release issued by Glenmark on Saturday, June 20, the company successfully developed the active pharmaceutical ingredient and formulation for FabiFlu through its own in-house R&D team.

‘Glenmark filed the product for clinical trial with India’s drug regulator DCGI and became the first pharmaceutical company in India to receive approval for conducting phase 3 clinical trial on mild to moderate COVID-19 patients,’ the press release said.

What improvement has it shown in Covid-19 patients and what studies has Glenmark cited?

Glenmark claimed that Favipiravir shows clinical improvements of up to 88 per cent in Covid-19, with rapid reduction in viral load by four days. The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.

In India, a randomised multi-centre study was done on Indian patients to test the drug’s efficacy and safety with standard of care vs standard of care alone in mild to moderate Covid-19, the company said. The study enrolled 150 patients. The study’s details are yet to be published in a peer-reviewed paper.

In its press release, the company cited four studies; two from China and one reach from Russia and Japan. One of the studies done on 80 patients in China studied the efficacy of Favipiravir vis-à-vis anti-retroviral drugs Lopinavir and Ritonavir. Favipiravir treatment led to a quicker reduction in viral load compared to the other drugs. In the second Chinese study, 236 patients were enrolled.

Favipiravir showed a better rate of clinical recovery on seventh day compared Umifenovir, another antiviral drug. It also led to a quicker relief from fever and cough. The observational study in Japan comprising 2,141 patients with mild to moderate symptoms showed clinical improvement using Favipiravir.

Is the government conducting trials to test the efficacy of this drug?

Yes. The Council of Scientific and Industrial Research (CSIR) had done end-to-end synthesis of Favipiravir in April. Earlier this week, CSIR got approvals from DGCI to conduct multi-centre Phase-II trials of the drug.

Government Rs 50 lakh covid cover for healthworkers extended till September

New Delhi: The government has extended the Rs 50 lakh insurance scheme for about 22 lakh healthcare providers for another three months till September as there is no respite from COVID-19 pandemic.

The scheme implemented by New India Assurance was to end on June 30, 2020 as per the announcement made by Finance Minister Nirmala Sitharaman as part of the Rs 1.70 lakh Pradhan Mantri Garib Kalyan package in March.

The insurance provides a comprehensive personal accident cover of Rs 50 lakh to a total of around 22.12 lakh public healthcare providers, including community health workers, who may have to be in direct contact and care of patients suffering from coronavirus infection and who may be at risk of being impacted by this.

Insurance Scheme for health workers in government hospitals and healthcare centres operationalised with effect from March 30, 2020, an official statement said, adding the scheme has been extended up to September.

The scheme is funded through the National Disaster Response Fund, operated by the Ministry of Health and Family Welfare.

Doctors, nurses, paramedics, sanitation workers and a few others working in hospitals under the central and state governments will be covered under the insurance scheme.

While announcing the scheme, the Finance Minister had said, safai karamcharis, ward-boys, nurses, ASHA workers, paramedics, technicians, doctors and specialists and other health workers would be covered by the special insurance scheme.

“Any health professional, who while treating COVID-19 patients, meet with some accident, then he/she would be compensated with an amount of Rs 50 lakh under the scheme,” she had said.

All government health centres, wellness centres and hospitals of the Centre as well as states would be covered under this scheme, she had said.

Glenmark launches Covid-19 drug after DCGI nod

Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19. The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).

FabiFlu is the first oral Favipiravir-approved medication for the treatment of Covid-19, the company said in a statement. “This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added. FabiFlu has demonstrated an encouraging response in mild to moderate Covid-19 patients during clinical trials, Saldanha said. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications, he noted.

“Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country,” Saldanha said. The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14. Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate Covid-19 symptoms. It offers rapid reduction in viral load within four days and provides faster symptomatic and radio logical improvement, the drug maker added.

Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate Covid-19 cases, it said. The drug firm had successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its in-house R&D team. It had then filed the product for clinical trial with country’s drug regulator DCGI and became the first pharmaceutical company in India to receive approval for conducting phase 3 clinical trial on mild to moderate Covid-19 patients.

Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. Last month, Glenmark also announced that it is conducting another clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult Covid-19 patients in India. India on Saturday saw another record spike of 14,516 new Covid-19 cases in a single day, pushing the tally to 3,95,048, while the death toll rose to 12,948 with 375 new fatalities, according to Union Health Ministry data.

8,000 teachers write to Amit Shah for 3 months salary

Image Source : FILE PHOTO

Around 8,000 teachers working in North Delhi Municipal Corporation, who are waiting for their salaries from last three months, write to Home Minister Amit Shah.(Representational image)

Schools were asked not to force parents to pay fee during the lockdown period which became a likely reason for non-payment of teachers’ salary for almost an equivalent amount of time. Now, around 8,000 teachers working in North Delhi Municipal Corporation, who are waiting for their salaries from last three months, have written to Union Home Minister Amit Shah regarding the same.

They had earlier appealed in the court too.

Municipal Corporation Teachers Association General Secretary Ramnivas Solanki on Friday said, “Today we have also written to Home Minister Amit Shah asking for help, in which we have apprised him that during this corona pandemic outbreak all the teachers are working for 12 hours. We are not only distributing ration to the poor people but we are also helping the migrant labourers and also in the treatment centres.”

He said, “We have been on the forefront in this fight against the pandemic. Apex court is also directing to pay the salaries of the doctors and health workers but they are ignoring the teachers while teachers are also the frontline corona warriors.”

The letter states that ‘teachers have not received the salary of March, April and May, while the month of June is also coming to an end. The arrears of the Seventh Pay Commission have not been received for the last four years. The bills of the arrears have not been paid for the last 10 years. The teacher recruitment bill of the children have not been paid for the last five years. Medical bills have not been paid for years. In such a situation, if a teacher or his/her family member has to get treatment he/she has to borrow money for that.”

Teachers are extremely disappointed as they have not received the salaries. On June 15, CAT ordered that three months’ salary and pension will be paid to all the teachers of North Corporation and pensioners within 15 days. On June 18, the High Court also directed the North MCD to pay salaries of all the teachers within a week.

(With inputs from IANS)

Galwan Valley clashes: 10 Army soldiers released by Chinese PLA after three days

By Mayank Singh

Express News Service

NEW DELHI: The Chinese Army released 10 soldiers from their captivity on Thursday, three days after the violent clashes at the Galwan Valley.

The sources informed that 10 soldiers were returned back unharmed after the Division Commander level talks. The group of 10 included two officers.

As per Army statement, four critically injured soldiers were now stable. While 18 were getting treated in Leh itself, 58 more would join duty in a week or 10 days as they had minor injuries only.

Army had clarified during the day that all soldiers were accounted for.

“It is clarified that there are no Indian Troops Missing In Action.” said Army.

The soldiers were missing since evening of Monday, June 15 when the Chinese Army soldiers attacked the Indian troops and killed 20 of them including the Commanding Officer of the local unit.

The Indian soldiers had gone for Patrolling Point 14 to verify the compliance of agreements reached between the Army Corps Commanders of both sides on June 6. The Chinese had to move back from the standoff location.

The chinese attacked Indian soldiers with rods and bamboo sticks studded with iron nails. The chinese attacking party was fully prepared with riot gears like the sticks, shield, elbow and knee guards.

While the Indian troops had their personal weapon with them but did not breach the agreement of 1996.

There was an agreement with China signed in November 1996 that neither side can open fire guns or use explosives within 2 kilometres of LAC. They carry the weapons but barrel is kept pointing down.